Background: The identification of the factors associated with severe asthma may shed some light on its etiology and on the mechanisms of its development. We aimed to describe asthma severity using the Global Initiative for Asthma (GINA) classification and to investigate its determinants in a cross-sectional, population-based sample in Europe. Methods: In the European Community Respiratory Health Survey II (1999–2002), 1,241 adults with asthma were identified. Severity was assessed using the 2002 GINA classification (intermittent, mild persistent, moderate persistent, severe persistent) and it was related to potential determinants by a multinomial logistic model, using the intermittent group as the reference category for relative risk ratios. Results: About 30% of asthmatic subjects were affected by moderate-to-severe asthma. Sensitization to Cladosporium was associated with a more than 5-fold greater risk of having (mild, moderate or severe) persistent asthma than intermittent asthma. Persistent asthma was positively associated with sensitization to house dust mite, nonseasonal asthma, an older age at asthma onset, and chronic cough and phlegm. Sensitization to cat increased the risk of severe asthma only. Smoking was more strongly associated with asthma severity in men, while rhinitis was more strongly associated with asthma severity in women. Conclusions: One third of the asthmatic population have moderate-to-severe asthma. Sensitization to perennial indoor allergens, particularly Cladosporium, is strongly associated with asthma severity. The role of smoking and rhinitis in determining asthma severity may differ between the sexes, and it should be further investigated.

1.
Global Initiative for Asthma: Global strategy for asthma management and prevention, 2006. www.ginasthma.com (accessed November 2008).
2.
Vollmer WM: Assessment of asthma control and severity. Ann Allergy Asthma Immunol 2004;93:409–413.
3.
Global Initiative for Asthma: Global strategy for asthma management and prevention, 2002. www.ginasthma.com (accessed November 2008).
4.
Fuhlbrigge AL, Adams RJ, Guilbert TW, et al: The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002;166:1044–1049.
5.
Cazzoletti L, Marcon A, Janson C, et al: Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007;120:1360–1367.
6.
Burney PGJ, Luczynska C, Chinn S, Jarvis D; for the European Community Respiratory Health Survey: The European Community Respiratory Health Survey. Eur Repir J 1994;7:954–960.
7.
The European Community Respiratory Health Survey Steering Committee: The European Community Respiratory Health Survey II. Eur Respir J 2002;20:1071–1079.
8.
Chinn S, Jarvis D, Melotti R, et al: Smoking cessation, lung function, and weight gain: a follow-up study. Lancet 2005;365:1629–1635.
9.
Chinn S, Burney P, Jarvis D, Luczynska C; on behalf of the European Community Respiratory Health Survey (ECRHS): Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1997;10:2495–2501.
10.
Quanjer PhH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Eur Respir J 1993;6(suppl 16):5–40.
11.
Williams RL: A note on robust variance estimation for cluster-correlated data. Biometrics 2000;56:645–646.
12.
National Heart Lung and Blood Institute; National Asthma Education and Prevention Program: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, 2007. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (accessed November 2008).
13.
Taylor DR, Bateman ED, Boulet LP, et al: A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545–554.
14.
Zureik M, Neukirch C, Leynaert B, et al; European Community Respiratory Health Survey: Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 2002;325:411–414.
15.
Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM: The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006;27:615–626.
16.
Targonski PV, Persky VW, Ramekrishnan V: Effect of environmental molds on risk of death from asthma during the pollen season. J Allergy Clin Immunol 1995;95:955–961.
17.
Black PN, Udy AA, Brodie SM: Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 2000;55:501–504.
18.
Peat JK, Tovey E, Mellis CM, Leeder SR, Woolcock AJ: Importance of house dust mite and Alternaria allergens in childhood asthma: an epidemiological study in two climatic regions of Australia. Clin Exp Allergy 1993;23:812–820.
19.
Denning DW, O’Driscoll BR, Powell G, et al: Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009;179:11–18.
20.
Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD: Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997;100:S2–S24.
21.
Custovic A, Taggart SC, Francis HC, Chapman MD, Woodcock A: Exposure to house dust mite allergens and the clinical activity of asthma. J Allergy Clin Immunol 1996;98:64–72.
22.
Tunnicliffe WS, Fletcher TJ, Hammond K, et al: Sensitivity and exposure to indoor allergens in adults with differing asthma severity. Eur Respir J 1999;13:654–659.
23.
Sarpong SB, Karrison T: Sensitization to indoor allergens and the risk for asthma hospitalization in children. Ann Allergy Asthma Immunol 1997;79:455–459.
24.
Sarpong SB, Karrison T: Skin test reactivity to indoor allergens as a marker of asthma severity in children with asthma. Ann Allergy Asthma Immunol 1998;80:303–308.
25.
Langley SJ, Goldthorpe S, Craven M, et al: Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma. J Allergy Clin Immunol 2003;112:362–368.
26.
Bousquet J, Boushey HA, Busse WW, et al: Characteristics of patients with seasonal allergic rhinitis and concomitant asthma. Clin Exp Allergy 2004;34:897–903.
27.
Ulrik CS: Outcome of asthma: longitudinal changes in lung function. Eur Respir J 1999;13:904–918.
28.
de Marco R, Bugiani M, Cazzoletti L, et al; ISAYA study group: The control of asthma in Italy. A multicentre descriptive study on young adults with doctor diagnosed current asthma. Allergy 2003;58:221–228.
29.
de Marco R, Cazzoletti L, Cerveri I, et al; ISAYA Study Group: Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol 2005;138:225–234.
30.
de Marco R, Marcon A, Jarvis D, et al; European Community Respiratory Health Survey Therapy Group: Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol 2006;117:1249–1256.
31.
Palombini BC, Villanova CA, Araujo E, et al: A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest 1999;116:279–284.
32.
Lange P, Parner J, Vestbo J, Schnohr P, Jensen G: A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194–1200.
33.
Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG Jr: Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992;146:1345–1348.
34.
Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B: Longitudinal methods for describing the relationship between pulmonary function, respiratory symptoms and smoking in elderly subjects: the Tucson Study. Eur Respir J 1993;6:342–348.
35.
Osborne ML, Vollmer WM, Linton KLP, Buist AS: Characteristics of patients with asthma within a large HMO: a comparison by age and gender. Am J Respir Crit Care Med 1998;157:123–128.
36.
Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG: Allergic rhinitis and sinusitis in asthma: differential effects on symptoms and pulmonary function. Chest 2006;130:429–435.
37.
Day A, Ernst P, Glick L, Zimmerman S, Chapman KR: Women and asthma: lessons from a gender analysis of the asthma in Canada Survey. J Asthma 2006;43:169–173.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.